toxylact: a06ab03 dantron
The first professional lActological database in the word
Dantron (ATC A06AB03) is a contact stimulant laxative that enhances colonic motility, but its use in breastfeeding is generally discouraged due to carcinogenicity concerns and lack of safety data in lactation.medpedia.framar+2
Drug class and composition
Dantron (also known as
1,8‑dihydroxyanthraquinone, chrysazin)
belongs to the ATC class A06AB03 “contact laxatives” within
“drugs for constipation.”wikipedia+3
It is an anthraquinone derivative that exerts a direct
irritating effect on the
colonic mucosa, classified as a stimulant laxative rather
than a bulk‑forming
or osmotic agent.medpedia.framar+1
Mechanism of action
Dantron increases intestinal motility by
stimulating sensory
nerve endings in the colonic mucosa, thereby enhancing
peristalsis and
facilitating defecation.gsrs-dev-public.ncats+1
This local action shortens colonic transit time and reduces
water reabsorption,
leading to softer stools and improved bowel emptying.wikipedia+1
Indications and therapeutic use
Historically, dantron has been used in adults
with chronic
constipation and in patients with hard stools to restore
more regular
defecation.medicamente+1
In many markets its use has become restricted or
discontinued because of safety
concerns; where available, it is generally reserved for
short‑term treatment of
constipation and sometimes in combination preparations for
bowel evacuation.precision.fda+2
Dosage and administration
The defined daily dose in the ATC/DDD index
for dantron is 50 mg
orally in adults, reflecting typical maintenance use in
chronic constipation.atcddd.fhi
Clinically, dantron has been given as oral tablets and, in
some settings,
rectal enemas, but current product availability varies by
country and is often
limited.drugcentral+2
Contraindications and precautions
Dantron is contraindicated in patients with
known hypersensitivity,
suspected or confirmed intestinal obstruction, acute
surgical abdominal
conditions, and severe inflammatory bowel disease.drugcentral+1
In the United States and some other jurisdictions dantron
has not been accepted
for use because of evidence of carcinogenic effects in
animal studies, which
has led to regulatory withdrawal or strong restrictions.drugfuture+2
Adverse effects
Reported adverse reactions include abdominal
pain, diarrhea,
headache, hypotension, arrhythmias, allergic reactions and
red discoloration of
urine (“pseudohaematuria”).synapse.patsnap+2
Dantron and related anthraquinones are associated with
pigment deposition in
colonic mucosa (melanosis coli) with prolonged use, and
long‑term exposure has
raised concerns regarding tumorigenesis in preclinical
models.drugfuture+1
Carcinogenicity and regulatory status
Preclinical studies have shown dantron to be
carcinogenic in
rodents, particularly causing intestinal and hepatic tumors,
which underpins
its limited approval status.wikipedia+1
Regulatory agencies in several countries have subsequently
withdrawn dantron‑containing
products or restricted them to specific indications and
short‑term use,
favoring safer laxatives for chronic constipation.mayoclinic+2
Use in special populations
In children, dantron is generally avoided
because of its
stimulant mechanism, potential for dehydration, and
theoretical carcinogenic
risk; safer alternatives such as polyethylene glycol or
docusate are preferred.mayoclinic+1
In older adults, chronic dantron therapy is discouraged due
to cumulative
toxicity, melanosis coli, and the availability of laxatives
with better long‑term
safety profiles.synapse.patsnap+1
Toxicological profile
At therapeutic doses dantron mainly causes
gastrointestinal
irritation, but overdose can lead to severe diarrhea,
electrolyte disturbances,
hypotension, and cardiac rhythm abnormalities.medpedia.framar+1
Systemic exposure has been linked to hepatic enzyme changes
in animal studies,
and its anthraquinone structure is considered a contributing
factor in DNA‑damaging
and carcinogenic potential.drugfuture+1
Lactation safety considerations
Evidence on dantron transfer into human breast
milk and infant
exposure is extremely limited, with only sparse case reports
and no robust
pharmacokinetic studies.hero.epa+1
Given its carcinogenicity in animals, lack of human safety
data, and the
availability of safer laxatives, expert sources generally
advise avoiding
dantron during breastfeeding and selecting alternatives with
established
lactation compatibility.hero.epa+2
Recommended alternatives in breastfeeding
For constipation in breastfeeding mothers,
osmotic agents such as
polyethylene glycol and stool softeners like docusate are
widely considered
compatible with lactation and are preferred over stimulant
anthraquinones.hero.epa+1
Non‑pharmacological measures (adequate fluid intake, dietary
fiber, physical
activity) should be optimized first, and if drug therapy is
needed, reference
sources such as LactMed and national prescribing services
recommend safer
choices than dantron.ncbi.nlm.nih+2
Clinical positioning in toxicological‑lactological practice
In a toxicological‑lactological context,
dantron should be
classified as a high‑concern laxative for breastfeeding
mothers because of
carcinogenic risk and insufficient infant safety data.hero.epa+1
Risk–benefit assessment strongly favors avoidance in
lactation, and dantron‑containing
products should not be first‑line for chronic constipation
in the general
population when safer agents are available.gsrs-dev-public.ncats+1



